STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #392 by analyst upside · 2026-06-27
OLMA
Olema Pharmaceuticals, Inc.
Healthcare · Market Cap $995M · P/E 0x
ANALYST PRICE TARGET
+257.3%
implied upside to consensus target
Current Price $11.39
Consensus Target $40.7
Bull Target $62.0
Bear Target $23.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $4.12
52-Week High $36.26
YTD Return -54.9%
FUNDAMENTALS
Market Cap $995M
P/E Ratio (TTM) N/A
Forward P/E -4.6x
EPS (TTM) $-2.03
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.12
52-Week High $36.26
Current Price $11.39
Bear Target $23.0
Bull Target $62.0
● Now $11.39 ● Target $40.7
TRADING DATA
Avg Volume 1.3M
YTD Return -54.9%
Analyst Count 10
Consensus Buy
Upside to Target +257.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Olema Pharmaceuticals, Inc. (OLMA) is currently trading at $11.39 with a Wall Street consensus price target of $40.7, implying potential upside of 257.3% over the next 12 months. 10 analysts currently cover OLMA, with a consensus rating of Buy — 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $62.0, while the most cautious has a target of $23.0.

OLMA operates in the Healthcare sector with a market capitalisation of $995M. The stock is down 54.9% year-to-date and is currently trading near the lower end of its 52-week range of $4.12 – $36.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OLMA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim — Reiterated
Buy → Buy 2026-05-13 62% win rate (8 calls)
Wolfe Research ● Initiated
Peer Perform 2026-03-27 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-18 43% win rate (7 calls)
Goldman Sachs — Reiterated
Buy → Buy 2026-03-18 Building track record
Citigroup — Reiterated
Buy → Buy 2026-03-17 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-03-17 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-09 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-02-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →